CHRI Seminar Series - Nanoparticles for Pediatric Cancer Imaging and Therapy

Monday, June 4, 2018

11:45 am

Center for Clinical Sciences Research (CCSR), Room # 4205

Sponsored by:
Child Health Research Institute

About the Seminar

The Stanford Child Health Research Institute presents its next seminar on Nanoparticles for Pediatric Cancer Imaging and Therapy.

Clinical contrast agents for MRI, which contain gadolinium, have been associated with nephrogenic sclerosis and gadolinium deposition in the brain. Therefore, a search for alternatives is currently underway. Ferumoxytol, an iron supplement, is FDA approved for the treatment of anemia and has been used by research group “off label” as an MR contrast agent. Drs. Heike Daldrup-Link and Suchismita Mohanty will provide an overview of the use of ferumoxytol nanoparticles for pediatric cancer imaging with MRI and PET/MRI, including safety data acquired in children thus far. The team recently demonstrated unique enhancement properties of nanoparticles in pediatric cancers, providing an immediate, non-invasive imaging test to track innate immune responses from macrophages in patients. They will also introduce novel approaches of using nanoparticles to specifically deliver therapeutic drugs to tumors, thereby providing cancer therapy without side effects to normal organs. 

Heike Daldrup-Link, MD – Dr. Daldrup-Link is a Professor of Radiology and, by courtesy, of Pediatrics (Hematology-Oncology) at Stanford University and Lucile Packard Children’s Hospital, with administrative roles as Director of Pediatric Molecular Imaging, Associate Chair for Diversity in the Radiology Department, and as Co-Director of the Cancer Imaging and Early Detection Program at the Stanford Cancer Institute. She is a past a recipient of CHRI awards, including the Transdisciplinary Initiatives Program (TIP).

Suchismita Mohanty, PhD - Dr. Suchismita Mohanty is a Research Scientist in the Radiology Department at Stanford. Her research focuses on cancer therapy and imaging, which includes glioblastomas, osteosarcomas and breast adenocarcinomas. Dr. Mohanty develops novel tumor-targeted theranostics for disrupting tumor vasculature and tumor metabolism and deploys multi-modality imaging to monitor therapy responses to anti-tumor drugs.

About the Series

The CHRI Education Seminars highlight compelling clinical topics, innovative research, and the latest developments in maternal child health, and serves as a forum for engaging in conversations with other researchers and scientists across the community. Students, faculty, and postdoctoral researchers are encouraged to attend the seminars. Seats are limited, and reservation is required. Limited lunch will be provided on a first come, first served basis. Attendees are welcome to bring their lunch to the event. Check out more CHRI Education Seminars.

When:
Monday, June 4, 2018
11:45 am – 12:45 pm
Where:
Center for Clinical Sciences Research (CCSR), Room # 4205
Admission:

You must register at https://chri-seminar-june4.eventbrite.com.

Tags:

Lecture / Reading 

Audience:
Faculty/Staff, Students, Members
Contact:
650-498-5444, roxannav@stanford.edu
More info:
Visit this website